tiprankstipranks
GSK announces EMA granted PRIME Designation for GSK5764227
The Fly

GSK announces EMA granted PRIME Designation for GSK5764227

GSK (GSK) announced that the European Medicines Agency, EMA, has granted Priority Medicines, PRIME, Designation for GSK5764227, its B7-H3-targeted antibody-drug conjugate, ADC, being evaluated for the treatment of patients with relapsed extensive-stage small-cell lung cancer, ES-SCLC. The PRIME Designation supports the development of medicines with potential to offer a major therapeutic advantage for patients. This is the second regulatory designation for GSK’227, following the US Food and Drug Administration’s decision to grant Breakthrough Therapy Designation in August 2024.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App